Abionic has announced a significant regulatory milestone: its 7-minute PSP (Pancreatic Stone Protein) test for early sepsis detection is now approved for pediatric use, extending its IVDR-compliant coverage from adults to children.

Sepsis remains the leading cause of death among young patients, with an estimated 25 million children affected globally each year and 85% of related deaths occurring in children under five. Early detection is vital, yet often elusive.

The PSP test offers a game-changing solution by identifying sepsis biomarkers before clinical symptoms emerge. Already in use for adult care since 2022, the test’s newly approved pediatric application promises to empower healthcare providers with faster diagnostic tools, enabling prompt and potentially life-saving intervention.